Physicians' Academy for Cardiovascular Education

Strong reduction CV events in FH patients with ApoB-inhibitor

May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Paul Barton Duell



ISA2015 | Clinical Breakthroughs Dr. Paul Barton Duell (endocrinologist, Portland, USA) presented a striking reduction of MACE with treatment with the antisense oligonucleotide against apoB mRNA mipomersen in a very high risk population.

News • 4-8-2014

Consensus document on diagnosis and management of homozygous familial hypercholesterolaemia

The Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society has reviewed the available data and established recommendations for improved diagnosis and management of HoFH.

News • 25-5-2015

CETP-inhibitor reduces non-HDL-cholesterol via reducing PCSK9 and enhancing hepatic remnant clearance

ISA 2015 Using a humanised mouse model, investigators reveal mechanism via which CETP-inhibitor anacetrapib reduces non-HDL-c.

News • 24-5-2015

Investigational drug has remodeling effect on HDL particles and induces cholesterol efflux

ISA 2015 Herman Kempen (Zurich, Switzerland) presented a new drug that may reduce the atherosclerotic plaque. MDCO-216, a complex of dimeric recombinant apolipoprotein A-1 Milano and a phospholipid (POPC), developed to mimic pre-beta HDL, induced ABCA1 mediated cholesterol efflux, and rapid HDL remodeling was seen. MDCO-216 was well tolerated.

News • 23-3-2015

EAS dedicated to address underdiagnosis and undertreatment of familial hypercholesterolaemia

European Atherosclerosis Society has launched global EAS FH Studies Collaboration (FHSC), which aims to address gaps in FH care and education worldwide, to promote early diagnosis and better treatment.  

News • 18-3-2015

More good news on novel lipid-lowering agent ETC-1002 in patients with hypercholesterolemia

Phase 2b results show that ETC-1002 (bempedoic acid) safely  and effectively lowers LDL-c levels when added to stable statin therapy, as compared with statin therapy alone.